Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Total Current Liabilities data on record, last reported at $1.5 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 17.36% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 17.36%, while the annual FY2025 figure was $1.8 million, 6.7% down from the prior year.
  • Total Current Liabilities reached $1.5 million in Q4 2025 per INM's latest filing, down from $1.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $4.6 million in Q4 2021 and bottomed at $1.3 million in Q3 2023.
  • Average Total Current Liabilities over 5 years is $2.2 million, with a median of $1.9 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: surged 70.32% in 2022, then tumbled 59.19% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $4.6 million in 2021, then tumbled by 48.01% to $2.4 million in 2022, then plummeted by 30.0% to $1.7 million in 2023, then increased by 6.57% to $1.8 million in 2024, then fell by 17.36% to $1.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $1.8 million in Q2 2025.